Investeerders
ALFASIGMA ANNOUNCES THE AGREEMENT FOR THE ACQUISITION OF 100% OF SOFAR, ITALIAN PHARMACEUTICAL COMPANY
ALFASIGMA S.p.A. has signed an agreement to acquire the entire share capital of SOFAR
8 augustus 2022
Actueel & Media / Actueel
Actueel
Investeerders
#LeaveYourMark with Alfasigma!
#LeaveYourMark will explore some of our key task: Improving patients' quality of
1 juli 2022
Therapeutische gebieden
Dag van de Hielprik 2022
De Neonatale Hielprik Screening (NHS) is in 1974 in Nederland ingevoerd en
28 juni 2022
Corporate
Website van Alfasigma Nederland is nu live!
Hier vind u informatie over onze producten en binnenkort ook meer informatie
21 april 2022
Corporate
Change at the top of Alfasigma. Pier Vincenzo Colli leaves, new CEO will be Francesco Balestrieri.
Chief Executive Officer of Alfasigma, Pier Vincenzo Colli, has decided to leave the
8 oktober 2021
Research & development
Alfasigma inaugurates the new Research&Development center in Pomezia named after its founder Marino Golinelli
Over 17 million EUR invested in LABIO 4.0 Marino Golinelli Two days
15 september 2021
Corporate
NOVAVIDO is born, the start-up that will study the first artificial liquid retina on humans
Alfasigma, Utopia SIS, Istituto David Chiossone and Club2021 will invest 6 million euros
23 juni 2021
Therapeutische gebieden
Online About Carnitine: the new portal for healthcare professionals
About Carnitine is the leading online global destination for healthcare professionals worldwide, offering
25 mei 2021
Corporate
Alfasigma Spa, corporate announcement
The merger between the 3 Italian companies Alfa Wassermann, Sigma-Tau and Biofutura
7 september 2017